 "Natco Pharma gets DCGI nod for hepatitis C drug; stock up 5%")
Shares of Natco Pharma were up 5% at Rs 1,882 after the company announced that it has received approvals from the Drug Controller General (India) for generic version of anti-hepatitis medicine sofosbuvir.
“Natco Pharma is pleased to announce that it is the 1st company in India to get approval for generic sofosbuvir tablets, 400mg, from Drugs Controller General (India),” the company said in a press release.
Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc., under its brand Sovaldi. Natco will market generic sofosbuvir under its brand HEPCINAT and through strategic partners in India.
Natco plans to price its generic medicine at an MRP of Rs 19,900 for a bottle of 28 tablets and expects to launch in India very soon, it added.
The company had recently signed a non-exclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.
The stock opened at Rs 1,812 and touched a record high of Rs 1,891 on NSE. The trading volumes on the counter more than doubled with a combined 251,348 shares changed hands on NSE and BSE till 1113 hours.
Meanwhile, in past two weeks the shares of pharmaceutical firm has rallied 41% from Rs 1,334 on February 26, after the company signed a non-exclusive licensing agreement with Gilead Sciences.
“Natco Pharma is pleased to announce that it is the 1st company in India to get approval for generic sofosbuvir tablets, 400mg, from Drugs Controller General (India),” the company said in a press release.
Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc., under its brand Sovaldi. Natco will market generic sofosbuvir under its brand HEPCINAT and through strategic partners in India.
Natco plans to price its generic medicine at an MRP of Rs 19,900 for a bottle of 28 tablets and expects to launch in India very soon, it added.
The company had recently signed a non-exclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.
The stock opened at Rs 1,812 and touched a record high of Rs 1,891 on NSE. The trading volumes on the counter more than doubled with a combined 251,348 shares changed hands on NSE and BSE till 1113 hours.
Meanwhile, in past two weeks the shares of pharmaceutical firm has rallied 41% from Rs 1,334 on February 26, after the company signed a non-exclusive licensing agreement with Gilead Sciences.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%